Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedSci Healthcare HoldingsHKSE:02415 79 ROE % is 0.80% as of Dec. 2025, which is 63% below its 10-year median of 2.15. GuruFocus rates HKSE:02415 with a GF Score™ of 79/100 and a GF Value™ of HK$1.44 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 621 Healthcare Providers & Services companies, MedSci Healthcare Holdings ranks worse than 65.06% on this metric.
The historical rank and industry rank for MedSci Healthcare Holdings's ROE % or its related term are showing as below:
HKSE:02415'
s ROE % Range Over the Past 10 Years
Min: -245.13 Med: 2.15 Max: 14.7
Current: 1.53
During the past 6 years, MedSci Healthcare Holdings's highest ROE % was 14.70%. The lowest was -245.13%. And the median was 2.15%.
HKSE:02415's ROE % is ranked worse than 65.06% of 621
companies
in the Healthcare Providers & Services industry
Industry Median: 6.01
vs HKSE:02415: 1.53
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, MedSci Healthcare Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MedSci Healthcare Holdings ROE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MedSci Healthcare Holdings's ROE % distribution charts can be found below:
* The bar in red indicates where MedSci Healthcare Holdings's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
MedSci Healthcare Holdings (HKSE:02415) has a ROE % of 0.80% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on MedSci Healthcare Holdings and its competitors. This is 63% below median its historical median of 2.15. According to the industry distribution chart, MedSci Healthcare Holdings ranks #404 out of 621 companies in the Healthcare Providers & Services industry, placing it in the top 65.1%.
Is MedSci Healthcare Holdings' ROE % too high?
MedSci Healthcare Holdings' current ROE % of 0.80% is 63% below median its 10-year median of 2.15. The Healthcare Providers & Services industry median ROE % is 6.01. MedSci Healthcare Holdings' value of 0.80% is 86.7% below this industry median. Based on the distribution chart, MedSci Healthcare Holdings ranks #404 out of 621 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, MedSci Healthcare Holdings has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MedSci Healthcare Holdings' ROE % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, MedSci Healthcare Holdings ranks #404 out of 621 companies for ROE %. This places MedSci Healthcare Holdings in the lower half of its industry. The industry median ROE % is 6.01. MedSci Healthcare Holdings' value of 0.80% is 86.7% below this benchmark. While the company's 10-year median is 2.15 vs. the industry median of 6.01, MedSci Healthcare Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 6.01, based on 621 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MedSci Healthcare Holdings's current ROE % of 0.80% is 86.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on MedSci Healthcare Holdings and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 6.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedSci Healthcare Holdings's current ROE % is 0.80%, which is 63% below median its own 10-year median of 2.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedSci Healthcare Holdings stock overvalued right now?
Based on GuruFocus' analysis, MedSci Healthcare Holdings (HKSE:02415) is currently considered Possible Value Trap. The stock's GF Value™ is HK$1.44, compared to a current price of HK$0.73 — trading 49.3% below its estimated fair value. The current ROE % is 0.80%, which is 63% below median its 10-year median of 2.15 and 86.7% below the Healthcare Providers & Services industry median of 6.01. MedSci Healthcare Holdings' overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For MedSci Healthcare Holdings (HKSE:02415), the current ROE % is 0.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MedSci Healthcare Holdings (HKSE:02415) Overvalued in 2026?
Based on GuruFocus' analysis, MedSci Healthcare Holdings stock appears to be undervalued.
The current stock price of HK$0.73 is trading 49.3% below its estimated GF Value™ of HK$1.44.
GuruFocus considers MedSci Healthcare Holdings to be Possible Value Trap.
Key valuation signals for HKSE:02415:
ROE %: 0.80% (63% below median its 10-year median of 2.15)
GF Value™: HK$1.44 vs. price of HK$0.73 (49.3% below fair value)
Industry Position: 86.7% below the Healthcare Providers & Services median (#404 of 621)
No single metric tells the full story. See the HKSE:02415 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MedSci Healthcare Holdings Ltd is an investment holding company. It operates online professional physician platforms in China. The principal activities of the company are the provision of physician platform solutions, precision omni-channel marketing solutions, and real-world study solutions in the People's Republic of China.
79GF Score
Get the complete analysis for HKSE:02415
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02415 has been successfully added to your 
